Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/42—Oxazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Definitions

• This invention relates generally to pharmaceutical formulations and, in particular, to an antioxidant stabilizer system for pharmaceutical formulations containing compounds such as isoxazole derivatives used for the treatment of Irritable Bowel System (IBS).
• IBS Irritable Bowel System
• irritable Bowel Syndrome is a motor disorder consisting of altered bowl habits, abdominal pain, and the absence of detectable pathology. IBS is recognized by its symptoms, which are markedly influenced by psychological factors and stressful life situations.
• compositions and a method for testing IBS in mammals including humans are shown in U.S. Patent No. 5,434,134, which patent is incorporated herein by reference.
• the method comprises administering to a mammal in need of IBS treatment, an effective dose of a compound of the formula I.
• R is hydrogen, C1-C3 alkyl, allyl, or CH2
• R' is hydrogen, C1-C3 alkyl, allyl, — cm - ⁇ 1 or — (CH2)n -x; n is to 1 to 5;
• X is an optionally substituted phenyl, C1-C3 alkoxy, or C1-C3 alkylthio;
• R 2 and R 3 are independently hydrogen, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 alkylthio, halo, CN, or phenyl; or together are — (CH2) P — ; p is 3 to 6;
• Y is -CH2-, -O-, -SO-m; m is 0,1 , or 2; or a pharmaceutically acceptable acid addition salt or solvate thereof.
• the '134 patent also discloses pharmaceutical formulations adapted for the treatment of IBS comprising a compound of formula I and a pharmaceutically acceptable carrier, diluent or excipient therefor.
• Another object of the invention is to provide a stabilizer system for materials corresponding to the compound of formula I.
• a further object of the invention is to provide a stabilizer system for pharmaceutical formulations containing materials having oxidizable groups such as amino, phenolic, hydroxyl amino, aldehyde, unsaturated compounds such as alkenes, isoxazole, sulfoxide, sulfone and mercapto and chemically stable pharmaceutical formulations containing the stabilizer system.
• materials having oxidizable groups such as amino, phenolic, hydroxyl amino, aldehyde, unsaturated compounds such as alkenes, isoxazole, sulfoxide, sulfone and mercapto and chemically stable pharmaceutical formulations containing the stabilizer system.
• R 1 is hydrogen, C1-C3 alkyl, allyl,
• R 2 and R 3 are independently hydrogen, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 alkylthio, halo, CN, or phenyl; or together are — (CH2) P — ; p is 3 to 6;
• Y is -CH2-, -O-, -SO-m; m is 0,1 , or 2; or a pharmaceutically acceptable acid addition salt or solvate thereof; an organic carboxylic acid containing more than 1 carboxylic acid group preferably 2 acid groups; and an antioxidant or mixture of antioxidants.
• Halo refers to bromine, chlorine, fluorine or iodine.
• Optionally substituted phenyl means a phenyl ring which may contain one or two substituents from the following list: C1-C3 alkyl, C1-C3 alkoxy, C1-C3 alkylthio, halo, NO2 and CN.
• Acids commonly employed to form such salts are inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like, and organic acids such as p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p- bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid and the like. Examples of such pharmaceutically acceptable salts thus -7-
• Preferred pharmaceutically acceptable acid addition salts are those formed with mineral acids such as hydrochloric acid and hydrobromic acid, and those formed with organic acids such as maleic acid.
• R 1 is propyl; ' c) R 2 and R 3 are independently hydrogen or C1-C3 alkyl; e) R 2 and R 3 are together -(CH) P , where p is 3 to 6; f) Y is O or -(CH2)-.
• each of the compounds exists as its individual d- and l-stereoisomers and also as the racemic mixture of such isomers. Accordingly, the compounds of the present invention include not only the dl-racemates but also their respective optically active d-and l-isomers.
• pharmaceutically effective amount represents an amount of compound of formula I which is capable of binding to both serotonin 1A and Mi receptors.
• the specific dose of compound formula I administered will, of course, be determined by the particular circumstances surrounding the case, including, for example, the compound administered, the route of administration, and the condition being treated.
• a typical daily dose is about 0.1 mg to about 10 mg or more of the active compound of formula I.
• a preferred daily dose is about 0.25 to about 5 mg, and most preferably about 0.5 to about 3 mg.
• Suitable carriers, excipients, and diluents are lactose, dextrose, sucrose, sorbitol, mannitol, starches such as corn starch, gum acacia, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water syrup, methyl cellulose, methyl hydroxybenzoates, propyl hydroxybenzoates, talc, magnesium stearate, and mineral oil.
• the formulations may additionally include lubricating agents, wetting agents, emulsifying agents, suspending agents, preserving agents, sweetening agents, flavor agents, and the like.
• the compositions of the invention may be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing formulating procedures known in the art. -10-
• compositions containing active ingredients having the following groups are contemplated herein for use with the stabilizer system of the invention: amino, phenolic, hydroxyl amino, aldehyde, unsaturated compounds such as alkenes, isoxazole, sulfoxide, sulfone and mercapto.
• the stabilizer system of the invention comprises preferably an admixture of an organic carboxylic acid containing more than 1 carboxylic acid group and an antioxidant.
• An antioxidant may be defined as a material, usually an organic compound, added to a formulation to retard oxidation, deterioration, etc. of the ingredients in the formulation, typically the active ingredient.
• the organic carboxylic acid is preferably a dicarboxylic acid, and more preferably a hydroxy dicarboxylic acid and most preferably an ⁇ -hydroxy dicarboxylic acid selected from -11-
• the antioxidants are typically substituted phenolic compounds such as butylated hydroxyanisole, propyl gallate and butylated hydroxytoluene (BHT) and ascorbic acid, ascorbyl palmitate, alpha-tocopherol and biflavonoids.
• Antioxidants such as ascorbic acid and BHT when used in admixture with the organic carboxylic acid provide enhanced stability effects for comounds of Formula I as demonstrated hereinbelow. Because of its demonstrated effectiveness, a preferred stabilizer system comprises citric acid, ascorbic acid and BHT.
• the stabilizer system comprising an organic carboxylic acid and an antioxidant will generally contain, by weight, greater than 75% organic carboxylic acid, preferably 80 to 95 % and up to about 25% antioxidant, preferably 5 to 20%. It is preferred that an admixture of antioxidants be used in the formulation, but a single antioxidant compound may suitably be employed with the organic carboxylic acid for certain pharmaceutical formulations.
• the amount of the stabilizer system can vary widely. Broadly stated, the amount of the stabilizer system in the formulation unit does is, by weight of active ingredient, about 50 to 1 ,000% or more, preferably 250 to 600%.
• step 3 Add the solution of step 2 to the ingredients in the granulator and mix until a uniform, damp granulation is obtained.
• Formulations were prepared as shown hereinbelow in Table 1 . Formulations were prepared by blending together the ingredients in the amounts (in mgs) indicated below.

Landscapes

• Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Epidemiology (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
• Plural Heterocyclic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Anti-Oxidant Or Stabilizer Compositions (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Publications (1)

Family

ID=22009506

Family Applications (1)

Country Status (7)

Cited By (2)

Families Citing this family (31)

Citations (7)

Family Cites Families (11)

• 1998
  • 1998-04-08 US US09/057,260 patent/US5962488A/en not_active Expired - Fee Related
  • 1998-11-16 CA CA002327708A patent/CA2327708A1/en not_active Abandoned
  • 1998-11-16 JP JP2000543139A patent/JP2003522724A/ja active Pending
  • 1998-11-16 DE DE69833684T patent/DE69833684T2/de not_active Expired - Fee Related
  • 1998-11-16 AT AT98958610T patent/ATE318598T1/de not_active IP Right Cessation
  • 1998-11-16 WO PCT/US1998/024471 patent/WO1999052529A1/en not_active Ceased
  • 1998-11-16 EP EP98958610A patent/EP1067927B1/en not_active Expired - Lifetime
• 1999
  • 1999-04-12 US US09/290,904 patent/US6479529B1/en not_active Expired - Fee Related

Patent Citations (8)

Also Published As

Similar Documents

Legal Events